X4 Pharmaceuticals (XFOR) EV to CFO (2019 - 2026)

X4 Pharmaceuticals (XFOR) has reported EV to CFO for 8 consecutive years, with 18.99 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EV to CFO fell 2456.12% year-over-year to 18.99; the trailing twelve-month figure through Jun 2026 stood at 4.72 (down 2238.95% YoY), and the FY2025 full-year result was 0.56, up 205.01% from the prior year.
• EV to CFO declined to 18.99 in Q2 2026 per XFOR's latest filing, from 15.54 in the prior quarter.
• Across five years, EV to CFO topped out at 3.09 in Q4 2025 and bottomed at 246.43 in Q1 2024.
• Historically, EV to CFO has averaged 70.91 across 5 years, with a median of 49.14 in 2022.
• The sharpest annual moves came in 2025 and 2026: EV to CFO jumped 246.04% in 2025, then plunged 24028.31% in 2026.
• Over 5 years, EV to CFO stood at 92.74 in 2022, then sank by 69.96% to 157.63 in 2023, then surged by 98.66% to 2.11 in 2024, then surged by 246.04% to 3.09 in 2025, then plunged by 715.4% to 18.99 in 2026.
• According to Business Quant data, EV to CFO over the past three periods registered 18.99, 15.54, and 3.09 for Q2 2026, Q1 2026, and Q4 2025 respectively.